Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic546 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Clinical trials
2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (268)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01393249 | PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL(AAP2008) | completed | — | 31 | Rigshospitalet, DenmarkOTHER | 1 | Dec 9, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 |
| clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01401322 | Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00874562 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02953730 | The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents | completed | Phase 4 | 9 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00015587 | Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)(CCLS) | completed | — | 3,523 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Oct 12, 2016 | clinicaltrials |
| NCT00862719 | Sitagliptin Umbilical Cord Blood Transplant Study | completed | Phase 2 | 29 | Indiana UniversityOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02894645 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | unknown | Phase 4 | 500 | National University Hospital, SingaporeOTHER | 2 | Sep 30, 2016 | clinicaltrials |
| NCT01331590 | Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia | completed | Early Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT01051154 | Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia(DHA-ALL) | completed | Phase 2 | 72 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01036009 | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | completed | Phase 2 | 43 | University of California, San FranciscoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | terminated | — | 88 | Stanford UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01014195 | Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors | completed | — | 237 | St. Jude Children's Research HospitalOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | Clare TwistOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01150669 | Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia | completed | — | 18 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT01540578 | Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia | completed | — | 70 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT01625143 | Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia | completed | — | 40 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT00898404 | Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate | completed | — | 150 | Children's Oncology GroupNETWORK | 1 | May 11, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02759822 | Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | unknown | — | 30 | Leonardo Javier ArcuriOTHER_GOV | 1 | May 3, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00750659 | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01461538 | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | completed | Phase 2 | 84 | Seagen Inc.INDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01253720 | PACE CALL: Weight Loss Study for Childhood Leukemia Survivors | completed | N/A | 38 | Huang, Jeannie, M.D.INDIV | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00526175 | LAL-BR/2001: Study Treatment to Low Risk ALL | completed | Phase 4 | 150 | PETHEMA FoundationOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2016source: clinicaltrials